Antihypertensive AgentsHypertensionBlood PressureHydrochlorothiazideDiureticsAtenololAngiotensin-Converting Enzyme InhibitorsCalcium Channel BlockersAmlodipineHydralazineMethyldopaAdrenergic beta-AntagonistsSodium Chloride Symporter InhibitorsMinoxidilRats, Inbred SHRBendroflumethiazideDoxazosinAngiotensin II Type 1 Receptor BlockersTetrazolesCaptoprilAngiotensin Receptor AntagonistsDihydropyridinesLisinoprilNordefrinGlutamyl AminopeptidaseClonidineEnalaprilDose-Response Relationship, DrugIndapamidePropanolaminesLabetalolDrug Therapy, CombinationBlood Pressure Monitoring, AmbulatoryBenzimidazolesGuanfacineNifedipineLosartanHeart RatePrazosinDiltiazemAdrenergic alpha-AntagonistsHypertension, RenalRenin-Angiotensin SystemImidazoline ReceptorsPerindoprilBlood Pressure DeterminationTreatment OutcomeReninBiphenyl CompoundsRats, Inbred WKYDouble-Blind MethodPropranololInterleukin-1betaTime FactorsChlorthalidonePatient ComplianceKidneyFumaratesSystoleValineClinical Trials as TopicImidazolesDesoxycorticosteroneMedication AdherenceHypertension, RenovascularKidney Failure, ChronicBenzopyransDrug CombinationsPhenylacetatesHormone AntagonistsHemodynamicsRisk Factorsbeta 2-MicroglobulinReceptors, Adrenergic, betaDiabetic NephropathiesAdministration, OralCardiovascular DiseasesRats, Sprague-DawleyFollow-Up StudiesDopamine AntagonistsArteriesTrichlormethiazideExcitatory Amino Acid AntagonistsProteinuriaCardiovascular SystemNeurokinin-1 Receptor AntagonistsInterleukin 1 Receptor Antagonist ProteinVasodilator AgentsProspective StudiesAortaAmidesDiabetes Mellitus, Type 2Narcotic AntagonistsDelayed-Action PreparationsHistamine H2 AntagonistsRandomized Controlled Trials as TopicKidney DiseasesDiabetes ComplicationsThiazidesSympathetic Nervous System